BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1120@pharmaconomics
DTSTAMP:20260707T033632Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:DTIL Phase 2 — ECUR-506
DESCRIPTION:Phase 2 trial results for ECUR-506 in Neonatal Onset OTC Deficiency are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1357874/000162828026001955/a20260112jpmrelease.htm\n\nTrack it: https://pharmaconomics.com/e/1120
URL:https://pharmaconomics.com/e/1120
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DTIL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR